p63 antagonizes Wnt-induced transcription

Cell Cycle

Volumn 9, Issue 3, 2010, Pages 580-587

  Drewelus, Isabella ^a   Göpfert, Constanze ^a,c   Hippel, Cathrin ^a   Dickmanns, Antje ^a   Damianitsch, Katharina ^a   Pieler, Tomas ^a   Dobbelstein, Matthias ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c PAUL EHRLICH INSTITUT   (Germany)

Author keywords

p63; Squelching; TCF LEF; Transcription; Wnt signaling

Indexed keywords

BETA CATENIN; LYMPHOID ENHANCER FACTOR 1; NP63 ALPHA PROTEIN; PROTEIN P63; REGULATOR PROTEIN; SMALL INTERFERING RNA; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN; LEF1 PROTEIN, HUMAN; PHOSPHOPROTEIN; TP63 PROTEIN, HUMAN; TP73L PROTEIN, XENOPUS; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; XENOPUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; EPITHELIUM; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; REPRESSOR GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; XENOPUS; ANIMAL; ANIMAL EMBRYO; BIOLOGICAL MODEL; GENE SILENCING; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MORPHOGENESIS; PHOSPHORYLATION; PRENATAL DEVELOPMENT; PROTEIN BINDING;

ANIMALS; BETA CATENIN; BODY PATTERNING; EMBRYO, NONMAMMALIAN; GENE KNOCKDOWN TECHNIQUES; GENES, REPORTER; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MODELS, BIOLOGICAL; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BINDING; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS; WNT PROTEINS; XENOPUS; XENOPUS PROTEINS;

EID: 77951898593     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.3.10593     Document Type: Article

References (39)

1. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002; 18:90-5.
2. Mills AA, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-13.
3. Yang A, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-8.
4. DasGupta R, Fuchs E. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development 1999; 126:4557-68.
5. Chu EY, et al. Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development 2004; 131:4819-29.
6. Alonso L, Fuchs E. Stem cells in the skin: waste not, Wnt not. Genes Dev 2003; 17:1189-200.
7. Patturajan M, et al. [Delta]Np63 induces [beta]-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1:369-79.
8. Brabletz T, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179:56-65.
9. Eger A, Stockinger A, Schaffhauser B, Beug H, Foisner R. Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of {beta}-catenin and upregulation of {beta}-catenin/lymphoid enhancer binding factor-1 transcriptional activity. J Cell Biol 2000; 148:173-88.
10. Kim K, Lu Z, Hay ED. Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int 2002; 26:463-76.
11. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and upregulation of genes involved in invasion and metastasis. Cancer Res 2006; 66:7589-97.
12. Xiaolian G, Philip JC, Linda B, Karin N. p63 contributes to cell invasion and migration in squamous cell carcinoma of the head and neck. Cancer Lett 2008; 263:26-34.
13. Urist MJ, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002; 161:1199-206.
14. Signoretti S, et al. p63 Is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157:1769-75.
15. Koga F, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003; 9:5501-7.
16. Koga F, et al. Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms. Br J Cancer 2003; 88:740-7.
17. Lee H-o, et al. A dominant negative form of p63 inhibits apoptosis in a p53-independent manner. Biochem Biophys Res Commun 2006; 344:166-72.
18. Thievessen I, Seifert HH, Swiatkowski S, Florl AR, Schulz WA. E-cadherin involved in inactivation of WNT//[beta]-catenin signalling in urothelial carcinoma and normal urothelial cells. Br J Cancer 2003; 88:1932-8. (Pubitemid 36829670)
19. Jho E-h, et al. Wnt/{beta}-Catenin/Tcf signaling induces the transcription of axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002; 22:1172-83.
20. Gill G, Ptashne M. Negative effect of the transcriptional activator GAL4. Nature 1988; 334:721-4.
21. Martin ML, Lieberman PM, Curran T. Fos-Jun dimerization promotes interaction of the basic region with TFIIE-34 and TFIIF. Mol Cell Biol 1996; 16:2110-8. (Pubitemid 26123731)
22. Ghioni P, et al. Complex Transcriptional Effects of p63 Isoforms: Identification of Novel Activation and Repression Domains{dagger}. Mol Cell Biol 2002; 22:8659-68.
23. Leucht P, Minear S, Ten Berge D, Nusse R, Helms JA. Translating insights from development into regenerative medicine: The function of Wnts in bone biology. Semin Cell Dev Biol 2008; 19:434-43.
24. Reis-Filho JS, Simpson PT, Fulford LG, Martins A, Schmitt FC. p63-driven nuclear accumulation of betacatenin is not a frequent event in human neoplasms. Pathol Res Pract 2003; 199:785-93. (Pubitemid 38239871)
25. Kim K, Lu Z, Hay ED. Direct evidence for a role of beta-Catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int 2002; 26:463-76.
26. Stefansson IM, Salvesen HB, Akslen LA. Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients. Int J Cancer 2006; 118:1227-33.
27. Morita M, et al. Expression of deltaNp63 in squamous cell carcinoma of the esophagus. Anticancer Res 2005; 25:3533-9.
28. Wang X, et al. p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 2002; 9:216-9.
29. DeYoung MP, et al. Tumor-specific p73 upregulation mediates p63 dependence in squamous cell carcinoma. Cancer Res 2006; 66:9362-8.
30. Yang A, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2:305-16.
31. Morin PJ, et al. Activation of beta-Catenin-Tcf Signaling in Colon Cancer by Mutations in beta-Catenin or APC. Science 1997; 275:1787-90.
32. Heyninck K, Beyaert R. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF[kappa]B activation at the level of TRAF6. FEBS Letters 1999; 442:147-50. (Pubitemid 30042563)
33. Willert K, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003; 423:448-52.
34. Veeman MT, Slusarski DC, Kaykas A, Louie SH, Moon RT. Zebrafish Prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr Biol 2003; 13:680-5. (Pubitemid 36453318)
35. Shih I-M, Yu J, He T-C, Vogelstein B, Kinzler KW. The {beta}-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 2000; 60:1671-6.
36. Behrens J, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996; 382:638-42. (Pubitemid 26268958)
37. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against {beta}-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003; 9:1291-300.
38. Carroll DK, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 2006; 8:551-61.
39. Higashikawa K, et al. Snail-induced downregulation of {Delta}Np63{alpha} acquires invasive phenotype of human squamous cell carcinoma. Cancer Res 2007; 67:9207-13. (Pubitemid 47535907)